given how much work Acadia is doing at making Daybue accessible and how needed this is for Rett patients, i was expecting a 50% uptake. i now suspect it will be higher.
neurogene has released a statement about patients with Daybue enrolling in their trials. In many ways, Daybue looks to become the standard of care future trials will use as a baseline. At the very least, it will be a expected subgroup in trial design.
https://www.neurogene.com/patients-and-families/about-rett-syndrome/trofinetide/
given how much work Acadia is doing at making Daybue accessible...
-
- There are more pages in this discussion • 100 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.13 |
Change
0.020(0.15%) |
Mkt cap ! $1.678B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.44 | $13.07 | $5.021M | 378.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 11501 | $13.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.18 | 1539 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |